Abstract-LIM domain proteins are important regulators in cell growth, cell fate determination, cell differentiation, and remodeling of the cell cytoskeleton. LIM and cysteine-rich domains 1 (Lmcd1) is a novel protein that contain 2 LIM domains with regular spacing in the carboxy-terminal region. However, its roles in cardiac growth remain unknown. Here, we investigated whether Lmcd1 regulates cardiac hypertrophy in vitro and in vivo and elucidated the underlying molecular mechanisms. We used primary cultured cardiac myocytes and cardiac-specific Lmcd1 transgenic mice. In wild-type mice subjected to the aortic banding, cardiac hypertrophy was evident at 8 weeks. In transgenic mice, however, cardiac hypertrophy was significantly greater than that in wild-type mice, as estimated by heart weight:body weight ratio, cardiomyocyte area, and echocardiographic measurements, as well as cardiac atrial natriuretic peptide and B-type natriuretic peptide mRNA and protein levels. Our results further showed that cardiac fibrosis observed in wild-type aortic banding mice was augmented in transgenic aortic banding mice. Importantly, calcineurin activity and nuclear factor of activated T cells activation level were increased more in transgenic mice than those in wild-type mice after 8-week aortic banding. In vitro experiments in cardiac myocytes further revealed that angiotensin II-induced calcineurin activity and nuclear factor of activated T cells activation were enhanced by overexpression but blunted by downregulation of Lmcd1. In conclusion, our results suggest that Lmcd1 plays a critical role in the development of cardiac hypertrophy via activation of calcineurin/nuclear factor of activated T cells signaling pathway. Key Words: cardiac hypertrophy Ⅲ fibrosis Ⅲ Lmcd1 Ⅲ calcineurin Ⅲ NFAT C ardiac hypertrophy is a response of the myocardium to increased workload, characterized by an increase of myocardial mass and accumulation of extracellular matrix, leading to left ventricular (LV) dilatation, fibrosis, and impaired systolic function, and it potentates the development of ventricular arrhythmias, heart failure, and subsequent cardiovascular mortality. 1,2 Although initially a beneficial adaptive response, prolonged hypertrophy may result in ventricular dilatation and heart failure, which is increasing in prevalence and is a debilitating disease with high rates of mortality and morbidity. [3][4] [5] [6] However, antihypertensive therapies and aortic valve replacement are the only 2 treatments proven to effectively reverse both structural and functional cardiac abnormalities associated with pathological cardiac hypertrophy. Understanding the underlying processes regulating cardiac remodeling will allow us to identify specific new therapies to improve the long-term outcomes of pathological cardiac hypertrophy in patients.
C ardiac hypertrophy is a response of the myocardium to increased workload, characterized by an increase of myocardial mass and accumulation of extracellular matrix, leading to left ventricular (LV) dilatation, fibrosis, and impaired systolic function, and it potentates the development of ventricular arrhythmias, heart failure, and subsequent cardiovascular mortality. 1, 2 Although initially a beneficial adaptive response, prolonged hypertrophy may result in ventricular dilatation and heart failure, which is increasing in prevalence and is a debilitating disease with high rates of mortality and morbidity. [3] [4] [5] [6] However, antihypertensive therapies and aortic valve replacement are the only 2 treatments proven to effectively reverse both structural and functional cardiac abnormalities associated with pathological cardiac hypertrophy. Understanding the underlying processes regulating cardiac remodeling will allow us to identify specific new therapies to improve the long-term outcomes of pathological cardiac hypertrophy in patients.
LIM domain proteins are well recognized as key components of the regulatory machinery of the cell and are important regulators in cell growth, cell fate determination, cell differentiation, and remodeling of the cell cytoskeleton. 7 LIM domains are composed of Ϸ55 amino acids with 8 highly conserved residues. The LIM consensus sequence has been defined as CX2CX16-23HX2CX2CX2CX16-21CX2(C/H/D), and all of the identified human LIM sequences show a slightly broader consensus sequence. 7 A wide variety of eukaryotic organisms contain LIM domain proteins. Currently, there are 135 identifiable LIM-encoding sequences located within 58 genes in the human genome. LIM proteins have been found in both the nucleus and the cytoplasm. Therefore, most characterized LIM proteins can interact directly or indirectly with different proteins, transcriptional factors, actin cytoskeletons, and kinases. [7] [8] [9] [10] LIM proteins function in diverse biological processes through interacting or binding of target proteins. 8 -10 LIM and cysteine-rich domains 1 (Lmcd1) was identified by screening of the expressed sequence tag database (dbEST) with partially overlapping expressed sequence tag clones, which encodes a family of LIM domain proteins. 11 The predicted Lmcd1 protein contains a novel cysteine-rich domain residing in the aminoterminal region and 2 LIM domains with regular spacing in the carboxy-terminal region. 11 Northern blot analysis indicated expression of the 1.7-kb transcript in many tissues, and it was found to be highly expressed in both cardiac and skeletal muscles. The potentially significant roles of Lmcd1 and its presence in human myocardial myofibrils implicate that LIM domain proteins might be associated with cardiac growth. Therefore, the purpose of this study was to determine whether Lmcd1 can regulate cardiac growth in the condition of pathology and physiology and to elucidate the molecular mechanisms of Lmcd1 on cardiac growth in vitro and in vivo.
Materials and Methods

Materials
Antibodies for the calcineurin/nuclear factor of activated T cells (NFAT) signaling pathways were purchased from Cell Signaling Technology. The anti-Lmcd1 (reactive with mouse or human) antibody was purchased from Santa Cruz Biotechnology. Antibodies for collagen I and connective tissue growth factor were ordered from Abcam. All of the other antibodies were purchased from Santa Cruz Biotechnology. [ 3 H]leucine was purchased from Amersham. The bicinchoninic acid protein assay kit was purchased from Pierce. Cell culture reagents and all of the other reagents were obtained from Sigma.
Transgenic Mice, Animal Models, Echocardiography, and Cardiac Catheterization
The study protocol was approved by the animal care and use committee of our hospital. The details for transgenic (TG) mice generation and the aortic banding (AB) model are given in the online Data Supplement (available at http://hyper.ahajournals.org). Echocardiography was performed using a SONOS 5500 ultrasound (Philips Electronics) with a 15-MHz linear array ultrasound transducer. Cardiac catheterization was performed using a 1.4-F Millar catheter-tip micromanometer catheter, which was inserted through the right carotid artery into the left ventricle. The detailed information is available in the online Data Supplement.
Cardiac Morphology Analysis
After blood samples were taken, hearts were cleared by perfusion with PBS, arrested in diastole with 10% KCl, weighted, fixed by perfusion with 10% paraformaldehyde, embedded in paraffin, and sectioned at 5 m or snap-frozen in liquid nitrogen for RNA and protein analysis. Sections were stained with hematoxylin/eosin for histopathology. For myocyte cross-sectional area, sections were stained with hematoxylin/eosin. A single myocyte was measured with an image quantitative digital analysis system (Image-Pro 4.5). The outline of 120 myocytes was traced in each group. To determine collagen deposition, tissue sections were stained with picrosirius red in saturated picric acid solution. With the use of an image analysis system, these sections were analyzed morphometrically. Fibrillar collagen was identified in the picrosirius-stained sections by its red appearance.
Recombinant Adenoviral Vectors and Cell Culture
We used replication-defective adenoviral vectors expressing the full-length rat Lmcd1 gene under the control of the cytomegalovirus promoter and a control adenoviral vector expressing the green fluorescent protein. Primary cultures of cardiac myocytes were prepared as described. [12] [13] [14] For details, please see the online Data Supplement. ]Leucine incorporation was measured as described previously. 13, 14 Calcineurin activity was measured as the dephosphorylation rate of a synthetic phosphopeptide substrate and was determined in lysates of whole ventricular tissues and cardiac myocytes, and NFATluciferase assay was performed as described previously. 15 Cardiac myocytes were transfected with 0.5 g of NFAT luciferase reporter construct (ordered from Addgene), and 10 L of LipofectAMINE reagent (Invitrogen) was used as the control plasmid DNA, according to the manufacturer's instructions. For details, please see the online Data Supplement.
Northern and Western Blot Analysis and Quantitative Real-Time PCR
Whole RNA was extracted from cardiac tissue with TRIzol reagent according to the manufacturer's instructions (Invitrogen). RNA (30 g) was run on a 1% agarose/formaldehyde gel at 120 V for 2 hours. The RNA was transferred to a nylon membrane by vacuum for 1.5 hours and cross-linked by UV wave. Protein extracts from different groups of myocardium (50 g) were fractionated on a 10% polyacrylamide gel, transferred to nitrocellulose membranes, and probed with various antibodies. Specific protein expression levels were normalized to either the GAPDH protein for total cell lysate and cytosolic protein or the Lamin-B1 protein for nuclear protein. For real-time PCR, we quantified PCR amplifications using SYBR Green PCR Master Mix (Applied Biosystems) and normalized results against GAPDH gene expression.
Coimmunoprecipitation Experiments
For transient transfection and coimmunoprecipitation experiments, mammalian expression plasmids for calcineurin A and Lmcd1 were ordered from Addgene and subsequently cloning into cytomegalovirus promoter-based vectors containing a Myc or Flag tag. Cultured primary cardiac myocytes were transfected with 1 g of expression plasmids for full-length forms of calcineurin A and Lmcd1 using LipofectAMINE reagent (Invitrogen). The detailed information for coimmunoprecipitation is described in the online Data Supplement.
Statistical Analysis
All of the values are expressed as meanϮSEM. The differences in the data simply between 2 groups were determined by a Student t test. Comparisons among groups on all of the other data were assessed by 2-way ANOVA followed by the Bonferroni post hoc test. A value of PϽ0.05 was considered statistically significant.
Results
Lmcd1 Expression Is Regulated in Response to AB
To determine the response of Lmcd1 to hypertrophic stresses, we analyzed the mRNA and protein levels of Lmcd1 after AB or sham surgery for different durations by Northern blot and Western blot assays. Intriguingly, both mRNA and protein expression were markedly upregulated after 4 weeks of AB but not in the sham group ( Figure 1A and 1B).
Overexpression of Lmcd1 Augments Cardiac Hypertrophy In Vitro
To investigate the effects of Lmcd1 on cardiac hypertrophy, we first examined its effect in primary cultured cardiac myocytes. We generated an adenoviral vector with the Lmcd1 gene under the control of the cytomegalovirus promoter. Expression of exogenous Lmcd1 protein in myocytes was detected by Western blot ( Figure S1A , available in the online Data Supplement). We also screened 3 short hairpin (sh) Lmcd1 and found that the third one markedly inhibited Lmcd1 protein expression in cardiac myocytes ( Figure S1A) . Therefore, the third shLmcd1 was chosen for the following experiments. Lmcdl overexpression significantly enhanced 
Overexpression of Lmcd1 Augments Cardiac Hypertrophy in Response to AB
To further examine whether Lmcd1 is involved in the regulation of cardiac hypertrophy, we generated TG mouse lines with full-length human Lmcd1 cDNA under the control of the ␣-myosin heavy chain promoter ( Figure S2A ). Four lines of TG mice were confirmed by Western blot ( Figure  S2B ). These lines were viable and fertile, and there were no detectable differences in cardiac size and structure between TG and wild-type (WT) mice at 10 weeks of age. We analyzed Lmcd1 protein levels in various tissues of TG mice by Western blot using anti-human Lmcd1 antibody. We found a robust expression of human Lmcd1 protein in the heart, but it was not detected in the other organs ( Figure S2C ). Among 4 established lines of the adult TG mice, the first, third, and fourth lines that expressed the higher levels of the human Lmcd1 protein in the heart did not show obvious difference in response to stress. Therefore, the first line was used for further experiments. We then subjected these mice to AB-induced pressure overload for 8 weeks to explore the possible role of Lmcd1 in pathological hypertrophy. The results showed that Lmcd1 TG animals displayed a marked increase in cardiac hypertrophy compared with WT litter- mates. AB-induced increases in the heart weight:body weight ratio and lung weight:body weight ratio were higher in TG mice compared with WT controls (Table S1 ). Analysis of the cardiomyocyte cross-sectional area from the histological sections revealed a significantly larger cell size in TG mice after AB than in WT controls (Table S1 and Figure 3 ). Echocardiographic analysis was further performed to evaluate geometric remodeling of the left ventricle in response to AB (Table S1 ). Although the intraventricular septum and posterior wall thickness were significantly increased in both TG and WT mice after AB, Lmcd1 TG mice displayed substantially enlarged LV chambers 8 weeks after AB (Table  S1 ). The fractional shortening was significantly decreased in TG mice compared with WT controls after 8 weeks of AB (Table S1 ). In addition, pressure overload-induced hypertrophy in TG animals was accompanied by extensive fibrosis, as indicated by picrosirius red staining (6.2% of fibrosis in WT AB versus 11.8% in TG AB; Figure S3C ). Furthermore, the mRNA expression and protein expression of atrial natriuretic peptide, B-type natriuretic peptide, and ␤-myosin heavy chain (markers of pathological hypertrophy), as well as transforming growth factor-␤1, procollagen type I ␣1 (Col1␣1), procollagen type III ␣1(Col3␣1), and connective tissue growth factor (markers of fibrosis), were significantly higher in AB-operated TG mice compared with AB-operated WT animals ( Figure S3A through S3E) , suggesting that Lmcd1 efficiently augments cardiac remodeling by modulating the expression of hypertrophic and fibrotic markers.
Overexpression of Lmcd1 Accelerates the Activation of Calcineurin/NFAT Signaling
Muscle LIM protein is required for calcineurin/NFAT signaling at the sarcomeric Z disc. 16 Therefore, Lmcd1 may regulate cardiac growth by activating calcineurin/NFAT signaling. To test this hypothesis, we exposed cardiomyocytes to 1 mol/L of Ang II infected with Ad-Lmcd1 or Ad-shLmcd1. Calcineurin phosphatase activity significantly increased after treatment with Ang II, and such an increase was evidently enhanced by infection with Ad-Lmcd1 but blocked by AdshLmcd1 ( Figure S4A ). Furthermore, calcineurin activity was also elevated by 43% in WT mice and by 93% in TG mice after AB ( Figure 4A ). Our data further showed that infection of cardiomyocytes with Ad-Lmcd1 significantly promoted the Ang II-induced NFAT nuclear translocation, whereas infection with Ad-shLmcd1 markedly blocked NFAT nuclear translocation ( Figure S4B ). To examine whether the alterations in NFAT nuclear translocation affected NFAT transcriptional activity, cardiomyocytes were transfected with a luciferase reporter plasmid driven by 3 NFAT binding sites. Treatment with Ang II significantly increased NFAT transcriptional activity, and such an increase was exacerbated by infections with Ad-Lmcd1 but blocked by Ad-shLmcd1 ( Figure S4C ). Myocyte-enriched calcineurin interacting protein 1 (MCIP1) is known to be a direct transcriptional target of calcineurin/NFAT signaling in cardiomyocytes. 17 Our studies showed that infection of Ad-shLmcd1 almost completely blocked the Ang II-induced increase of MCIP1.4, whereas infection of Ad-Lmcd1 augmented the Ang IIinduced increase of MCIP1.4 ( Figure S4C ). The levels of nuclear NFATc4 and MCIP1.4 were significantly increased in the hearts of WT mice and elevated more in TG mice after AB ( Figure 4B and 4C ). To investigate whether Lmcd1 directly interacts with calcineurin protein, coimmunoprecipitation was preformed. Indeed, we found that Lmcd1 coimmunoprecipitated with calcineurin ( Figure S4D ). These findings suggest that overexpression of Lmcd1 directly augments the activation of calcineurin/NFAT signaling in vitro and in vivo in response to hypertrophic stimuli and then exacerbates cardiac hypertrophy. 
Blocking Calcineurin/NFAT Signaling Blunts Cardiac Hypertrophy in TG Mice
To further confirm the critical role of calcineurin/NFAT signaling in vivo, the calcineurin inhibitor cyclosporin A (CSA) was used. Lmcd1 TG mice were divided into 4 groups: (1) sham/CSA (nϭ11); (2) sham/vehicle (nϭ10); (3) AB/ CSA (nϭ14); and (4) AB/vehicle (nϭ15). CSA (25 mg/kg per day, SC) or vehicle was treated 1 week before surgery and then continued for 4 weeks after AB or sham. Four weeks after AB, vehicle-treated TG mice displayed classic pressureoverloaded hypertrophic responses, including fetal gene program reactivation, increases in LV diastolic posterior wall thickness, and increases in heart weight:body weight ratios, as well as the cardiac myocyte area ( Figure S5A and S5B), compared with sham controls. These changes were significantly attenuated in the CSA-treated AB TG mice. The induction of fetal genes, including atrial natriuretic peptide, B-type natriuretic peptide, and ␤-myosin heavy chain by AB, was also significantly attenuated in the CSA-treated TG hearts ( Figure S5C ). Taken together, our findings indicate that CSA prevents the development of cardiac hypertrophy in TG mice by blocking the calcineurin/NFAT signaling.
Discussion
In the case of pathological cardiac hypertrophy, although the increased heart size is initially a compensatory mechanism, sustained hypertrophy can ultimately lead to a decline in LV function and, thus, represents an independent risk factor for heart failure. 18 Therefore, it is necessary to clarify the mechanism of cardiac hypertrophy and find the key targets for the treatment of pathological hypertrophy. In the present study, we demonstrate that Lmcd1 mediates cardiac hypertrophy, likely by promoting the activation of the calcineurin/ NFAT pathway in vitro and in vivo ( Figure 5 ). These novel findings suggest that inhibiting Lmcd1 is critically important in protecting the heart from pressure overload. According to the current LIM domain protein classification, [7] [8] [9] [10] Lmcd1 belongs to the group 3 proteins, which contain Ն1 LIM domain at the C-terminal region. The N-terminal region of the novel predicted protein contains a cysteine-rich domain: C-X2-C-X3-C-X5-H-X5-C-X2-C-X1-C-X4-H-C. Most LIM proteins of group 3 are cytoplasmic and participate in protein-protein interactions with the cytoskeleton. 9, 19 Similar to other LIM domain proteins with 
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predominant expression in the skeletal muscle, the Lmcd1 protein might be involved in DNA-protein-protein interactions during muscle development and remodeling. However, until the present study, the (patho)physiological significance of Lmcd1 in cardiac responses to hemodynamic overload had not been recognized. To examine the role of Lmcd1 on cardiac hypertrophy, we used primary cultured cardiac myocytes and cardiac-specific human Lmcd1 gene overexpression in TG mice. Here, we report that cardiac Lmcd1 protein expression can be markedly induced by pressure overload. Moreover, we have investigated the pathological role of Lmcd1 in early cardiac responses to pressure overload and in the modulation of a pivotal hypertrophic signaling pathway.
To determine the role of Lmcd1 in the heart to respond to stress, we subjected the TG mice to sham and transverse aortic constriction surgery. Compared with WT mice, TG mice responded differently to these procedures. At 8 weeks after the AB surgery, TG mice displayed marked reactivation of the fetal gene program: concentric cardiac hypertrophy, as evidenced by increased LV wall thickness and heart weight:body weight ratio. Compared with the WT AB group, the TG AB group showed greater reactivation of the atrial natriuretic peptide, B-type natriuretic peptide, and ␤-myosin heavy chain; greater cardiac hypertrophy; lower fractional shortening; and higher heart weight:body weight and lung weight:body weight ratios. These indicate that the overexpression of Lmcd1 exacerbates pathological cardiac responses to ABinduced LV pressure overload. Taken together, our in vitro and in vivo data indicated that overexpression of Lmcd1 augments cardiac hypertrophy, whereas inhibition of Lmcd1 attenuates hypertrophic responses. Therefore, Lmcd1 appears to be an endogenous and positive regulator of hypertrophic response. Cardiac fibrosis is one of the classic features of hypertrophy and is characterized by the expansion of the extracellular matrix attributed to the accumulation of collagen, especially collagen I and connective tissue growth factor. 20, 21 It is important to understand the mechanism that stimulates collagen deposition in the heart and to identify approaches to block these processes. One of the findings of this study revealed that Lmcd1 augments cardiac fibrosis and promotes expression of several fibrotic mediators mediated by pressure overload. In an attempt to elucidate mechanisms underlying the effect of Lmcd1 on fibrosis, we analyzed key components of transforming growth factor-␤1 signal transduction. Because transforming growth factor-␤ is a major activator of fibroblast differentiation and activation, it is, thus, is a key player in the fibrotic response. Activation of this signaling pathway is predicted to mediate fibrosis. In line with these notions, our results demonstrated that Lmcd1 promotes transforming growth factor-␤1 expression levels in vivo and concomitantly enhances collagen synthesis in cardiac fibroblasts. The biochemical mechanisms by which Lmcd1 functions in the heart remain unclear. A number of signaling cascades, including transcription factors, kinases, and G protein-coupled receptors, are implicated in the regulation of cardiac growth. 6, 18 Among these, the calcineurin/NFAT pathway has been shown to be a key signaling cascade that promotes cardiac hypertrophy. 22, 23 Calcineurin dephosphorylates NFATs in response to increased intracellular calcium and regulates gene expression in a variety of calcium-sensitive tissues, such as brain, muscle, and lymphocytes. 21, 22 Transcriptional activity of NFATs depends on dephosphorylation by calcineurin, which leads to nuclear translocation. [23] [24] [25] Recent studies revealed that muscle LIM protein directly associates with calcineurin, and this interaction is critical for calcineurin-NFAT signaling. 16, 17 Thus far, the direct effect of Lmcd1 on calcineurin/NFAT signaling has not been explored. This study demonstrates for the first time that increased Lmcd1 expression provokes a remarkable activation of calcineurin/NFAT signaling. Substrates of calcineurin phosphatase activity include most members of the NFAT family of transcription factors. Overexpression of Lmcd1 resulted in significantly upregulated NFAT activity and the nuclear translocation of NFATc4. MCIP1.4 is an endogenous modulator of calcineurin, the expression of which is controlled by calcineurin/NFAT. 26, 27 In cells, equilibrium is established between the abundance of MCIP1.4 protein and calcineurin activity. Therefore, MCIP1.4 protein abundance can serve as a functional surrogate for calcineurin activity. This is supported by our in vitro and in vivo results, in which treatment with Ang II or AB provoked marked increases in MCIP1.4 protein abundance and was especially much higher in the Lmcd1-overexpressed group. MCIP1.4 is involved in a variety of important physiological and pathological functions. It has been implicated in regulating cardiac hypertrophy, stress responses, angiogenesis, and neurological diseases, including Alzheimer disease and Down syndrome. 26, 27 More importantly, pharmacological inhibition of calcineurin signaling with cyclosporin A treatment in Lmcd1 TG mice attenuated cardiac hypertrophy and fibrosis and improved cardiac dysfunction. These findings suggest that calcineurin/NFAT signaling is the key signaling that Lmcd1 exerts its prohypertrophic effects.
In conclusion, our present work provided in vitro and in vivo evidence that cardiac Lmcd1 expression exacerbated cardiac hypertrophy via regulating calcineurin/NFAT signaling. Lmcd1 is a critical signaling molecule responsible for cardiac hypertrophy and fibrosis. These observations may have significant implications for the development of novel strategies for the treatment of cardiac hypertrophy and fibrosis through targeting of the calcineurin/NFAT signaling pathway. Additional studies are necessary to attain a better understanding of the effects of Lmcd1 on cardiac function and the effects of Lmcd1 inhibition in animal models of cardiac hypertrophy.
Perspectives
The current study provides a new insight into the role of the LIM domain protein Lmcd1 in the development of cardiac hypertrophy and fibrosis induced by pressure overload. Our findings suggest that Lmcd1 behaves as an endogenous and positive regulator of hypertrophic response. This finding may provide a novel therapeutic target for cardiac hypertrophy and fibrosis. Future studies are needed to investigate the molecular mechanisms in which Lmcd1 promotes calcineurin/ NFAT signaling in the heart using TG and knockout mice.
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Materials
Antibodies for the calcineurin/NFAT signaling pathways were purchased from Cell Signaling Technology. The anti-Lmcd1 (reactive with mouse or human) antibody was purchased from Santa Cruz Biotechnology. Antibodies for collagen I and CTGF were ordered from Abcam. All other antibodies were purchased from Santa Cruz Biotechnology. [ 3 H]-leucine was purchased from Amersham. The BCA protein assay kit was purchased from Pierce. Cell culture reagents and all other reagents were obtained from Sigma.
Transgenic Mice and Animal Models
All protocols were approved by institutional guidelines. All surgeries and subsequent analyses were performed in a blinded fashion for genotype. Human Lmcd1 cDNA construct containing fulllength human Lmcd1 cDNA (ordered from OriGene Company) was cloned downstream of the cardiac myosin heavy chain (MHC) promoter. Transgenic mice were produced by microinjection of the α-MHC-Lmcd1 construct into fertilized mouse embryos (C57 background). Four independent transgenic lines were established and studied. Transgenic mice were identified by PCR analysis of tail genomic DNA. Functional data and gene expression levels were analyzed in pairs of α-MHC-Lmcd1 (TG) and littermate nontransgenic (WT) male mice. Aortic banding (AB) was performed as described previously (1). Mice were anesthetized and horizontal skin incision was made at the level of the 2 to 3 intercostals space. Isolated the descending aorta; and a 7-0 silk suture was snared and pulled back around the aorta. A bent 27-gauge needle was then placed next to the aorta, and the suture was tied snugly around the needle and the aorta. After ligation, the needle was quickly removed, the chest and skin were closed, and the mice were allowed to recover. To serve as controls, age-matched animals underwent the same procedure without aortic banding. Doppler analysis was performed to ensure that adequate constriction of the aorta had been induced.
Echocardiography and Cardiac Catheterization
Echocardiography was performed using SONOS 5500 ultrasound (Philips Electronics, Amsterdam) with a 15-MHz linear array ultrasound transducer. The left ventricle (LV) was assessed in both parasternal long-axis and short-axis views at a frame rate of 120 Hz. Left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD) were measured from the M-mode tracing with a sweep speed of 50 mm/s at the mid-papillary muscle level. End-systole and end-diastole were defined as the phase with the smallest or largest area of LV, respectively. For hemodynamic measurements, mice were anesthetized and laid on a warm cushion maintained at 37±5°C and fixed in place with adhesive tape. A 1.4-F Millar catheter-tip micromanometer catheter was inserted through the right carotid artery into the LV. The position of the tip was monitored by the length of catheter advanced and observation of the pressure wave form. Hemodynamic measurements were recorded at baseline. Analog inputs from the pressure transducer were amplified using an ARIA (Millar Instruments Inc.) amplifier and digitized with a data-acquisition system (Harvard Apparatus) at a rate of 1,000 Hz. All parameters were calculated from the average of 30 consecutive beats from the stabilized stage.
Cardiac Morphology Analysis
After blood samples were taken, hearts were cleared by perfusion with PBS, arrested in diastole with 10% KCl, weighted, fixed by perfusion with 10% paraformaldehyde, embedded in paraffin, and sectioned at 5 µm or snap-frozen in liquid nitrogen for RNA and protein analysis. Sections were stained with hematoxylin and eosin (H&E) for histopathology. For myocyte cross-sectional area, sections were stained for membranes with FITC-conjugated Wheat germ agglutinin (WGA, Invitrogen Corp) and for nuclei with DAPI. Single myocyte was measured with an image quantitative digital analysis system (Image-Pro 4.5). The outline of 120 myocytes was traced in each section. To determine collagen deposition, tissue sections were stained with Sirius Red in saturated picric acid solution. With the use of an image analysis system, these sections were analyzed morphometrically. Fibrillar collagen was identified in the picrosirius-stained sections by its red appearance.
Northern blot, Western Blot Analysis and Quantitative real-time PCR
Whole RNA was extracted from cardiac tissue with TRIzol reagent according to the manufacture's instructions (Invitrogen, Carlsbad, CA). 30 µg RNA was run on a 1% agarose/formaldehyde gel at 120V for 2h. The RNA was transferred to a nylon membrane by vacuum for 1.5 h and cross-linked by UV wave. Probes of Lmcd1 (human and mouse) cDNA were generated by reverse transcription of heart mRNA and amplification of the resulting cDNA by the polymerase chain reaction. Protein extracts from different groups of myocardium (50 µg) were fractionated on a 10% polyacrylamide gel, transferred to nitrocellulose membranes, and probed with various antibodies. After incubation with a secondary peroxidase-conjugated antibody, signals were visualized by Chemiluminescence kit (Amersham, Sunnyvale, CA). Specific protein expression levels were normalized to either the GAPDH protein for total cell lysate and cytosolic protein, or the Lamin-B1 protein for nuclear protein. For real time-PCR, total RNA was extracted from frozen, pulverized mouse tissues using TRIzol (Invitrogen) and synthesized cDNA using oligo (dT) primers with the Advantage RT-for-PCR kit (BD Biosciences). We quantified PCR amplifications using SYBR Green PCR Master Mix (Applied Biosystems) and normalized results against glyceraldehydes-3-phosphate dehydrogenase (GAPDH) gene expression.
Recombinant Adenoviral Vectors and Cell Culture
We used replication-defective adenoviral vectors expressing the full-length rat Lmcd1 gene under the control of the cytomegalovirus promoter, and a control adenoviral vector expressing the GFP protein. We screened three lines of adenovirus generated from the shRNA constructs against rat Lmcd1 from SuperArray (Cat. No. KR47031G), and selected one that led to the greatest decrease in Lmcd1 levels for further experiments. The control shRNA virus from Superarray was used as control. We infected cardiac myocytes with Ad-Lmcd1, Ad-GFP, Ad-shLmcd1 or Ad-shRNA at a multiplicity of infection (MOI) of 100, resulting in 95-100% of cells expressing the transgenes without toxicity. Primary cultures of cardiac myocytes were prepared as described (2) . Cells from the hearts of 1-to 2-day-old Sprague-Dawley rats were seeded onto six-well culture plates at a density of 3 × 10 5 /well in MEM supplemented with 10% FCS. The culture medium was replaced after 24 h with serum-free medium containing BrdU (0.1 mM). On culture day 3, the cardiac myocytes were then infected with AdLmcd1 or Ad-shLmcd1 for 24 hours and subsequently stimulated with 1 µM Ang II for the indicated times. Viability was determined by cell number, frequency of contractions, cellular morphology and trypan blue exclusion.
[
3 H]-Leucine Incorporation [ 3 H]-Leucine incorporation was measured as described previously (3) . Briefly, cardiac myocytes were infected with different adenovirals for 24 hours and subsequently stimulated with Ang II and co-incubated with [ 3 H]-leucine (1 µCi/mL, Moravek Biochemicals Inc) for 48 h. At the end of the experiment, the cells were washed with Hanks' solution, scraped off the well, and then treated with 10% trichloroacetic acid at 4°C for 60 min. The precipitates were then dissolved in NaOH (0.2 N). Aliquots were counted with a scintillation counter.
Calcineurin Activity and NFAT-Luciferase Assays
Calcineurin activity was determined in lysates of whole ventricular tissues and cardiac myocytes as previously described (4) . For the phosphatase assay, RII peptide (Sigma) was phosphorylated by protein kinase A (Cell Signaling) in the presence of [γ-32 P]ATP overnight at 30°C in the presence of 1 mol/L Tris-HCl (pH 7.5), 0.1 mol/L dithiothreitol, and 0.1 mol/L MgCl 2 . Tissues were homogenized in lysis buffer. After the debris was removed by centrifugation, the supernatant was incubated with phosphorylated RII peptide for 30 minutes at 30°C. Okadaic acid (500 nmol/L) was added to the reactions to specifically suppress endogenous protein phosphatase PP1 and PP2A. NFAT-luciferase assay was performed as previously described (4) . Cells were transfected with 0.5 µg of NFAT luciferase reporter construct (ordered from Addgene in Boston), and 10 µl of LipofectAMINE reagent (Invitrogen) was used as control plasmid DNA, according to the manufacturer's instructions. Cells were infected with different adenoviral for 24 hours and then treated with Ang II for cardiac myocytes. Cells were harvested using passive lysis buffer (Promega) according to the manufacturer's protocol. The luciferase activity was normalized by control plasmid. All experiments were done in triplicate and repeated at least three times.
Co-immunoprecipitation experiments
For transient transfection and co-immunoprecipitation experiments, mammalian expression plasmids for Calcineurin A and Lmcd1 were ordered from Addgene and subsequently cloning into CMV promoter-based vectors containing a Myc or Flag tag. 3×10 5 primary cultured cardiac myocytes were transfected with 1 µg of expression plasmids for full-length forms of Calcineurin A and Lmcd1 using LipofectAMINE reagent (Invitrogen). Cardiac myocytes were then briefly sonicated, and debris was removed by centrifugation. Tagged proteins were immunoprecipitated for 3h at 4 °C using protein A/G-agarose and 1 µg of the appropriate antibody (monoclonal anti-FLAG or monoclonal anti-Myc). Subsequently, the pellet was washed with buffer and subjected to SDS-PAGE, transferred to polyvinylidene membranes and immunoblotting using anti-FLAG or anti-My antibody.
Statistical Analysis
All values are expressed as mean ± SEM. The differences in the data simply between two groups were determined by a Student's test. Comparison among groups on all of other data was assessed by One-Way ANOVA followed by Bonferroni's post hoc test. A value of P<0.05 was considered statistically significant. 
